{
    "medicine_id": "3e30baf100830301a77025f155dd1994ab9977f6",
    "platform_id": "DB06759",
    "metadata": {
        "name": "24 Multivitamins Minerals 1 mcg mL Injection solution concentrate",
        "composition": "1 mcg mL Fomivirsen",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for the local treatment of cytomegalovirus CMV retinitis in patients with acquired immunodeficiency syndrome AIDS when other therapy has been ineffective or is considered unsuitable FDA Label L1428",
            "contraindications": {
                "disease": "There has been one case of accidental overdose of fomivirsen with administration once bilaterally with 990 \u03bcg per eye vision was restored with anterior chamber paracentesis performed bilaterally L1428 According to the findings in Salmonella Microsome Ames and mouse lymphoma tests fomivirsen was not shown to be mutagenic In the in vivo mouse micronucleus assay fomivirsen was not clastogenic Animal reproductive studies or studies evaluating the carcinogenic potential of fomivirsen has not been conducted FDA Label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Fomivirsen is an antiviral agent that inhibits CMV replication in a dose dependent manner with a mean 50 inhibitory concentration between 0 03 and 0 2 \u03bcM in a number of _in vitro_ cell lines A31989 In human fibroblast cell lines the median effective inhibitory concentration EC50 of fomivirsen for virus antigen production was approximately 0 34 0 25 \u03bcM L1428 In a clinical trial administration of fomivirsen in patients with newly diagnosed CMV retinitis resulted in an increased median time to disease progression in the immediate treatment group versus delayed treatment group L1428",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}